Breaking News
Get 45% Off 0
⚖ What's the current risk profile of the stocks in my watchlist? (Yes, you can ask that.)
Chat with WarrenAI
Close

Sbiokasan Mid-small Cap Growth Equity Open (0P00012B2A)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
36,224.000 +103.000    +0.29%
06/06 - Closed. Currency in JPY
Type:  Fund
Market:  Japan
ISIN:  JP90C000A7B3 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 784M
Okasan Mid-Small Cap Growth Equity Open 36,224.000 +103.000 +0.29%

0P00012B2A Holdings

 
Comprehensive information about top holdings and Key Holding Information for the Okasan Mid-Small Cap Growth Equity Open (0P00012B2A) fund. Our Okasan Mid-Small Cap Growth Equity Open portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 5.410 5.410 0.000
Shares 94.590 94.590 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 10.579 15.704
Price to Book 1.634 1.874
Price to Sales 1.223 1.148
Price to Cash Flow 6.460 9.650
Dividend Yield 2.766 1.936
5 Years Earnings Growth 16.896 14.263

Sector Allocation

Name  Net % Category Average
Technology 25.450 24.973
Consumer Cyclical 23.480 13.908
Industrials 19.230 24.698
Healthcare 15.490 8.251
Basic Materials 8.930 7.515
Financial Services 2.530 6.917
Communication Services 2.210 6.884
Consumer Defensive 1.680 5.675
Energy 1.010 1.255

Region Allocation

  • Asia
  • Developed Markets

Top Holdings

Number of long holdings: 31

Number of short holdings: 0

Name ISIN Weight % Last Change %
  Japan Eyewear Holdings JP3389460001 5.78 2,454.00 +0.41%
  Daiei Kankyo JP3480470008 5.41 3,140.00 +1.29%
  Genda JP3386890002 5.37 855.00 +1.42%
  Gunze Ltd JP3275200008 4.87 3,590.0 +0.84%
  Union Tool Co JP3950600001 4.61 4,585.0 -1.19%
  PeptiDream JP3836750004 4.50 1,683.0 -0.71%
  Seika Corp JP3414200000 4.37 4,600.0 -0.22%
  Tamron Co Ltd JP3471800007 4.24 3,370.0 -0.44%
  Ffri JP3166830004 4.10 5,390.0 +0.19%
  Daikoku Denki JP3483100008 3.89 2,128.0 -1.80%

Top Equity Funds by SBI Okasan Asset Management Co., Ltd.

  Name Rating Total Assets YTD% 3Y% 10Y%
  Okasan Japan High Div Rebalance 124.71B 2.00 18.57 9.70
  Ok Asia O High Div Growth Eq Div 1M 79.35B -0.95 9.37 2.86
  Okasan World REIT Selection US 25.26B -8.17 3.05 5.57
  Okasan World REIT Selection Asia 21.18B -6.76 -1.32 3.86
  Okasan Japan New Technology Open 18.44B -6.52 11.01 10.88
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P00012B2A Comments

Write your thoughts about Sbiokasan Mid-small Cap Growth Equity Open
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email